Findx
EnglishEnglish
Dansk Dansk

CollPlant Biotechnologies Ltd. stock analysis OPHI.US

CollPlant Biotechnologies is a regenerative and aesthetic medicine company that produces recombinant human Type I collagen (rhCollagen) using a proprietary plant-based genetic engineering platform. The company's core business is centered on developing and commercializing medical aesthetics and 3D bioprinting technologies, particularly bioink products for print-based creation of tissues and organs, as well as aesthetic dermal and soft tissue filler products. Its revenue sources include sales of bioinks for 3D bioprinting, rhCollagen for aesthetic treatments, and rhCollagen-based products targeting tendinopathy and wound healing.

Secondary product lines include commercially available rhCollagen-based bioink platforms named Collink.3D 50, Collink.3D 90, and Collink.3D 50L, designed for different mechanical properties and tissue types. The company also develops a photocurable regenerative dermal filler aimed at skin rejuvenation, lifting, and facial contouring in cooperation with AbbVie, and 3D-bioprinted breast implants intended for tissue regeneration rather than permanent synthetic or silicone-based implants. Additionally, it markets products in Europe such as VergenixSTR, a soft tissue matrix for tendinopathy, and VergenixFG, a flowable rhCollagen-based gel for treatment of deep surgical incisions and wounds.

CollPlant operates primarily from Rehovot, Israel, with a wholly-owned subsidiary, CollPlant Ltd., owning its intellectual property and another subsidiary, CollPlant Inc., established in the United States though not operational as of its latest filings. Its products are being developed and commercialized globally, including in the United States, Canada, Europe, and Israel. The company generates revenue both through sales of its own products and through collaborations with other medical and biotech companies. Additionally, its business model entails ongoing research and development investment, with currently negative cash flows and net losses, and a reliance on additional financing and milestone agreements to support its operations until profitability.

Healthcare · Biotechnology · Biotechnology · Israel
Quality
Quality
Momentum
Momentum
Strength
Strength
Entry
Entry: Not yet
A classic falling-knife setup. Price is below SMA 20 and the moving averages are declining. Early bounces inside downtrends often fade. Wait for price to reclaim SMA 20 and for the slopes to stop falling before considering an entry.
Trend
Trend: Trend broken
Trend broken. Two or more consecutive closes below SMA 50 signal that the medium-term trend has flipped. Exiting here is the rule rather than the exception.
‹
›

Click to see warnings

Neg. values
‹
›
Years
Lower P/E (Bear)
Sign in to view
Fair Value
Sign in to view
Upper P/E (Bull)
Sign in to view
Analysts
Sign in to view
Price: Financials: Q2 FY2026 / FY2025TTM presentEstimates: UnavailableScored as: Standard companyEvidence: LimitedDetails

Freshness

  • Price through:
  • Latest annual period: FY2025 (); filed
  • Latest interim period: Q2 FY2026 (); filed
  • TTM period: ; used by: Quality, Strength
  • No future Diluted EPS estimate is available.
  • Target price: Date unknown, Analyst count unknown

Scoring profile

Effective scoring profile: Standard company

Report a suspected classification error

Score evidence

Quality: Limited; Limited confidence; TTM used
Business Momentum: Limited; Limited confidence; TTM not used
Strength: Limited; Limited confidence; TTM used
  • Business Momentum was calculated without one or more required inputs. One or more parts could not be assessed. We use 50 out of 100 for each missing part. This is an assumption, not a measured result. Latest surprise, Estimate revisions, Profitability could not be assessed because a required input is missing.
  • Quality was calculated without one or more required inputs. One or more parts could not be assessed. We use 50 out of 100 for each missing part. This is an assumption, not a measured result. Margin Stability could not be assessed because a required input is missing.
  • Strength was calculated without one or more required inputs. One or more parts could not be assessed. We use 50 out of 100 for each missing part. This is an assumption, not a measured result. Debt & Payment Capacity, Profitability Durability could not be assessed because a required input is missing.

Sources and adjustments

Remaining score inputs are provider supplied.

  • Debt to operating cash flow: derived by Findx
  • Net debt to EBITDA: derived by Findx

Key stock metrics

Blended P/E  :
P/E (last full year) :
N/A
N/A
Blended EPS  :
USD N/A
Blended EPS Yield  :
N/A
Dividend Yield :
(Trailing 12 months)
0.00%
Buyback Yield :
(Trailing 12 months)
-25.25%
Market Cap:USD 6.81 M
EUR 6.18 M

Valuation basis

Analyst price target
Yearly EPS growth  :
( years incl. estimates)
N/A

P/E Values

Upper P/E:
Fair Value P/E  :
Lower P/E:
Market P/E  :

EPS Estimates

:
N/A
:
N/A
:
N/A

About CollPlant Biotechnologies Ltd.

Description, revenue sources, strengths and weaknesses

DESCRIPTION

CollPlant Biotechnologies is a regenerative and aesthetic medicine company that produces recombinant human Type I collagen (rhCollagen) using a proprietary plant-based genetic engineering platform. The company's core business is centered on developing and commercializing medical aesthetics and 3D bioprinting technologies, particularly bioink products for print-based creation of tissues and organs, as well as aesthetic dermal and soft tissue filler products. Its revenue sources include sales of bioinks for 3D bioprinting, rhCollagen for aesthetic treatments, and rhCollagen-based products targeting tendinopathy and wound healing.

Secondary product lines include commercially available rhCollagen-based bioink platforms named Collink.3D 50, Collink.3D 90, and Collink.3D 50L, designed for different mechanical properties and tissue types. The company also develops a photocurable regenerative dermal filler aimed at skin rejuvenation, lifting, and facial contouring in cooperation with AbbVie, and 3D-bioprinted breast implants intended for tissue regeneration rather than permanent synthetic or silicone-based implants. Additionally, it markets products in Europe such as VergenixSTR, a soft tissue matrix for tendinopathy, and VergenixFG, a flowable rhCollagen-based gel for treatment of deep surgical incisions and wounds.

CollPlant operates primarily from Rehovot, Israel, with a wholly-owned subsidiary, CollPlant Ltd., owning its intellectual property and another subsidiary, CollPlant Inc., established in the United States though not operational as of its latest filings. Its products are being developed and commercialized globally, including in the United States, Canada, Europe, and Israel. The company generates revenue both through sales of its own products and through collaborations with other medical and biotech companies. Additionally, its business model entails ongoing research and development investment, with currently negative cash flows and net losses, and a reliance on additional financing and milestone agreements to support its operations until profitability.

ADDITIONAL INFO

It is very important that you understand this

Fair Value is an estimate, and you choose the basis it is built on. Do not invest based on our default without understanding how we calculate it.